Oral sorbinil, an aldose reductase inhibitor, will be administered in a double-masked randomized trial to diabetics with no or minimal diabetic retinopathy. This will be done to evaluate the effects of sorbinil on the development of diabetic retinopathy and further investigate the safety and toleration of sorbinil. The study will be conducted simultaneously in 11 research centers in the USA.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Intramural Research (Z01)
Project #
1Z01EY000198-01
Application #
3965381
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1986
Total Cost
Indirect Cost
Name
U.S. National Eye Institute
Department
Type
DUNS #
City
State
Country
United States
Zip Code